Fill in this information to identify the case:

Debtor 1 Nereid Therapeutics Incorporated

Debtor 2 (Spouse, if filing) _____

United States Bankruptcy Court for the: District of Delaware

Case number 26-10048

Official Form 410

Proof of Claim

04/25

Read the instructions before filling out this form. This form is for making a claim for payment in a bankruptcy case. Do not use this form to make a request for payment of an administrative expense. Make such a request according to 11 U.S.C. § 503.

Filers must leave out or redact information that is entitled to privacy on this form or on any attached documents. Attach redacted copies of any documents that support the claim, such as promissory notes, purchase orders, invoices, itemized statements of running accounts, contracts, judgments, mortgages, and security agreements. **Do not send original documents;** they may be destroyed after scanning. If the documents are not available, explain in an attachment.

A person who files a fraudulent claim could be fined up to $500,000, imprisoned for up to 5 years, or both. 18 U.S.C. §§ 152, 157, and 3571.

Fill in all the information about the claim as of the date the case was filed. That date is on the notice of bankruptcy (Form 309) **that you received.**

Part 1: Identify the Claim

1. **Who is the current creditor?**

Crystal Pharmatech Co., Ltd.
Name of the current creditor (the person or entity to be paid for this claim)

Other names the creditor used with the debtor _____

2. **Has this claim been acquired from someone else?**

☑ No
☐ Yes. From whom? _____

3. **Where should notices and payments to the creditor be sent?**
Federal Rule of Bankruptcy Procedure (FRBP) 2002(g)

Where should notices to the creditor be sent?	**Where should payments to the creditor be sent?** (if different)
Crystal Pharmatech Inc Name	Crystal Pharmatech Co., Ltd. Name
3000 Eastpark Blvd, Suite 500B Number Street	288 Jiangyun Road, Suzhou, China, 215123 Number Street
Cranbury NJ 08512 City State ZIP Code	Suzhou City State ZIP Code
Contact phone 925-558-5040	Contact phone +86-0512-69561921
Contact email _____	Contact email pm@crystalpharmatech.com

RECEIVED
FEB 12 2026
VERITA GLOBAL

Uniform claim identifier (if you use one):
_ _

4. **Does this claim amend one already filed?**

☑ No
☐ Yes. Claim number on court claims registry (if known) _____ Filed on _____ MM / DD / YYYY

5. **Do you know if anyone else has filed a proof of claim for this claim?**

☑ No
☐ Yes. Who made the earlier filing? _____



Part 2: Give Information About the Claim as of the Date the Case Was Filed

6. **Do you have any number you use to identify the debtor?**
   - ☑ No
   - ☐ Yes. Last 4 digits of the debtor's account or any number you use to identify the debtor: ____ ____ ____ ____

7. **How much is the claim?** $ 52,400.00 . **Does this amount include interest or other charges?**
   - ☑ No
   - ☐ Yes. Attach statement itemizing interest, fees, expenses, or other charges required by Bankruptcy Rule 3001(c)(2)(A).

8. **What is the basis of the claim?**
   Examples: Goods sold, money loaned, lease, services performed, personal injury or wrongful death, or credit card.
   Attach redacted copies of any documents supporting the claim required by Bankruptcy Rule 3001(c).
   Limit disclosing information that is entitled to privacy, such as health care information.
   Services performed

9. **Is all or part of the claim secured?**
   - ☑ No
   - ☐ Yes. The claim is secured by a lien on property.

   Nature of property:
   - ☐ Real estate. If the claim is secured by the debtor's principal residence, file a *Mortgage Proof of Claim Attachment* (Official Form 410-A) with this *Proof of Claim.*
   - ☐ Motor vehicle
   - ☐ Other. Describe: _____

   Basis for perfection: _____
   Attach redacted copies of documents, if any, that show evidence of perfection of a security interest (for example, a mortgage, lien, certificate of title, financing statement, or other document that shows the lien has been filed or recorded.)

   Value of property: $_____
   Amount of the claim that is secured: $_____
   Amount of the claim that is unsecured: $_____ (The sum of the secured and unsecured amounts should match the amount in line 7.)

   RECEIVED
   FEB 12 2026
   VERITA GLOBAL

   Amount necessary to cure any default as of the date of the petition: $_____

   Annual Interest Rate (when case was filed)_____%
   - ☐ Fixed
   - ☐ Variable

10. **Is this claim based on a lease?**
    - ☑ No
    - ☐ Yes. **Amount necessary to cure any default as of the date of the petition.** $_____

11. **Is this claim subject to a right of setoff?**
    - ☑ No
    - ☐ Yes. Identify the property: _____

12. **Is all or part of the claim entitled to priority under 11 U.S.C. § 507(a)?**

A claim may be partly priority and partly nonpriority. For example, in some categories, the law limits the amount entitled to priority.

☑ No

☐ Yes. *Check one:*

	Amount entitled to priority
☐ Domestic support obligations (including alimony and child support) under 11 U.S.C. § 507(a)(1)(A) or (a)(1)(B).	$_____
☐ Up to $3,800* of deposits toward purchase, lease, or rental of property or services for personal, family, or household use. 11 U.S.C. § 507(a)(7).	$_____
☐ Wages, salaries, or commissions (up to $17,150*) earned within 180 days before the bankruptcy petition is filed or the debtor's business ends, whichever is earlier. 11 U.S.C. § 507(a)(4).	$_____
☐ Taxes or penalties owed to governmental units. 11 U.S.C. § 507(a)(8).	$_____
☐ Contributions to an employee benefit plan. 11 U.S.C. § 507(a)(5).	$_____
☐ Other. Specify subsection of 11 U.S.C. § 507(a)(__) that applies.	$_____

* Amounts are subject to adjustment on 4/01/28 and every 3 years after that for cases begun on or after the date of adjustment.

Part 3: Sign Below

The person completing this proof of claim must sign and date it. FRBP 9011(b).

If you file this claim electronically, FRBP 5005(a)(3) authorizes courts to establish local rules specifying what a signature is.

A person who files a fraudulent claim could be fined up to $500,000, imprisoned for up to 5 years, or both. 18 U.S.C. §§ 152, 157, and 3571.

Check the appropriate box:

☑ I am the creditor.

☐ I am the creditor's attorney or authorized agent.

☐ I am the trustee, or the debtor, or their authorized agent. Bankruptcy Rule 3004.

☐ I am a guarantor, surety, endorser, or other codebtor. Bankruptcy Rule 3005.

I understand that an authorized signature on this *Proof of Claim* serves as an acknowledgment that when calculating the amount of the claim, the creditor gave the debtor credit for any payments received toward the debt.

I have examined the information in this *Proof of Claim* and have a reasonable belief that the information is true and correct.

I declare under penalty of perjury that the foregoing is true and correct.

Executed on date 02/04/2026
MM / DD / YYYY

Signature

Print the name of the person who is completing and signing this claim:

Name: Eva (First name) | (Middle name) | Deng (Last name)

Title: Chief Financial Officer

Company: Crystal Pharmatech Co Ltd
Identify the corporate servicer as the company if the authorized agent is a servicer.

RECEIVED
FEB 12 2026
VERITA GLOBAL

Address: 288 Jiangyun Road, SIP, Suzhou, China, 215123
Number Street

Suzhou
City State ZIP Code

Contact phone _____ Email _____

Crystal Pharmatech

Crystal Pharmatech Co., Ltd.
288 Jiangyun Road, SIP
Suzhou, China, 215123,
Tel: 86-0512-69561921

SUMMARY OF CLAIM

Debtor: Nereid Therapeutics Incorporated **Case No.:** 26-10048

Creditor: Crystal Pharmatech Co., Ltd.

---

1. Claim Overview

- **Total Claim Amount: $52,400.00**
- **Claim Type:** General Unsecured Claim
- **Basis for Claim:** Professional Research Services (B2B)
- **503(b)(9) Status:** No

2. Detailed Invoice List (Ref: Exhibit B)

Invoice Date	Invoice Number	Due Date	Amount (USD)
03/31/2025	#CP540U09CCA	04/30/2025	$11,500.00
07/03/2025	#CP540U09CCB	08/02/2025	$40,900.00
Total			**$52,400.00**

3. Service Fulfillment & Acceptance Summary (Ref: Exhibit A&C)

Date	Description	Details
03/26/2025	Contract Signing	Service Proposal signed by both parties
03/31/2025	Down Payment Invoice	First Payment Invoice #CP540U09CCA issued to Debtor via Email
05/22/2025	Change Order Signed	Change Order for additional work signed by both parties
06/30/2025	Report Delivery	All research services were completed, and the Final Research Report was delivered to the Debtor
07/03/2025	Final Payment Invoice	Final Payment Invoice #CP540U09CCB issued to Debtor via Email
07/04/2025	Client Acceptance	Debtor confirmed the payment

4. Supporting Documentation Index

Exhibit	Document Description	Page Range
Exhibit A	Proposal, Purchase Order, and Change Order	Page 2-9
Exhibit B	Copies of Unpaid Invoices	Page 10-11
Exhibit C	Service Delivery Evidence & Acceptance: *Exhibit C-1: Proof of Report Delivery* *Exhibit C-2: Invoice Submission Records* *Exhibit C-3: Client Acceptance Confirmation*	Page 12-15 *Page 12* *Page 13-14* *Page 15*

Crystal Pharmatech

Business Confidential
Co-Crystal Screening

Co-Crystal Screening

Proposal Date	March 3, 2025	**Proposal ID**	CP540U09
Client	Nereid Therapeutics Inc.	**Primary Contact**	Ivan Efremov
City, State	Boston, MA	**Email**	iefremov@nereidtx.com
Country	United States	**Expiration**	60 Days

Accepted and Approved for Crystal Pharmatech Co.,Ltd by:

Robert Wenslow
VP of Business Development US
Crystal Pharmatech Co.,Ltd

Signature:

Date: March 3, 2025

Accepted and Approved for Nereid Therapeutics Inc. by:

John F. Reilly
Chief Scientific Officer
Nereid Therapeutics Incorporated

Signature: John F. Reilly

Date: 26Mar2025

Crystal Pharmatech Co.,Ltd Phase and Formulation Selection Mission Statement

Vetting of API forms and formulations for First-in-Human studies is critical to maintaining the integrity of downstream processes. Crystal Pharmatech Co.,Ltd makes best-in-class decisions utilizing a data-driven, multi-disciplinary approach based on institutional knowledge and comparative analysis. We rely on the key, basic, solid-state scientific principles of physical properties, solubility, stability, processability and isolation complexity needed to ensure the API phase and formulation are understood to a level of detail ensuring downstream processes are robust.

Crystal Pharmatech

Proposal to Provide Services (PPS) Content

1. Project Summary

Client request Crystal Pharmatech to perform co-crystal screening for a promising small molecule compound. Crystal Pharmatech suggests the following workflow:

- Co-crystal Screening
- Co-crystal Scale Up and Phase Origin (Optional)
- Co-crystal Evaluation (Optional)

2. Specific Activities

Co-crystal Screening

- Perform computational cocrystal screening for target compound with co-formers (at least 50 co-formers) using COSMOtherm by calculating the excess enthalpy (Hex).
    - Recommend a list of co-formers with high likelihood of cocrystal formation based on the calculated Hex.
    - Requires knowledge of chemical structure
- Estimate solubility in at least 15 process relevant solvents at RT.
- Screen design (at least 100 experiments). Experiments should be done in two tiers and should include > 15 co-formers.
- Prepare blank counterions as needed.
- XRPD will be performed on all hits.
- Further characterization including TGA, DSC and PLM will be completed on up to 5 unique co-crystal forms. More forms can be characterized at an additional charge upon the Client's approval. This will result in a Change Order.

Co-crystal Scale Up and Phase Origin (Per hit) (Optional)

- Scale up hit to ~200-300mg.
    - Characterize scale up by XRPD, DSC, PLM, TGA, KF and/or GC.
- If anhydrate or hydrate, characterize by DVS.
- For cocrystal stoichiometry, characterize scale up by 1H NMR, or HPLC-CAD.

Co-crystal Evaluation (Per Hit) (Optional)

- After concurrence with client, 1, 4, 24 hrs (or other 3 timepoints after concurrence with client) solubility in water, SGF, FaSSIF and FeSSIF (or 4 media, depending on study requirement) will be measured at 37°C for co-crystal hit. All the samples will be tested for concentration (HPLC), pH and form conversion (XRPD).
- After concurrence with client, co-crystal hit will be used for 1 week physical and chemical stability study (25°C/60%RH and 40°C /75%RH). All the samples will be tested for purity (HPLC) and form conversion (XRPD).
- 50-100 mg of salt samples will be provided to client for PK study (if needed).
-

Table 1:

Crystal Pharmatech

Recommended Cost, Timing, and Material Needed			
Activity	**Cost**	**Timeline (Weeks)**	**Material (g)**
Co-crystal Screening	23,000	4	2
Total	***$23,000***	***4***	***2***

Table 2: Optional Cost, Timing, and Material Needed			
Activity	**Cost**	**Timeline (Weeks)**	**Material (g)**
Co-crystal Scale Up and Phase Origin (per hit)	3,000	1.5	1
Co-crystal Evaluation (per hit)	5,000	1.5	1
Total	***$8,000***	***3***	***2***

3. Desired Material and Background Information

Client will provide Crystal Pharmatech with material as requested in Table 1

Client will also provide:

- All solubility data collected to date.
- All background characterization or phase understanding data available to date
- All stability data collected to date is relevant to the execution of this proposal.
- Detailed HPLC method for the determination of compound integrity, if needed.
- Material Safety Data Sheet (MSDS). For highly potent compound (OEL < 1 $\mu g/m^3$) and/or compound with known or predicted cytotoxic activity, Crystal Pharmatech will review MSDS and handling procedures and accept or reject to work on the compound after evaluation. Therefore, it is highly recommended that the client provides the MSDS and handling information to Crystal Pharmatech BEFORE approving the proposal and shipping the compound.

4. Timelines

Crystal Pharmatech will start the workflow within 3 business days after the material is received. Subsequently, a kickoff meeting for project discussion will be given by the project manager unless the client requests to start prior to the sample's arrival. The desired work will be completed according to Table 1. Any work in addition to the above workflow will incur extra time and will be clearly communicated to Client through e-mail.

5. Sample Shipping/Disposal/Storage/Return

After the client confirms the acceptance of the final report, Crystal Pharmatech will reach out to the client for sample disposal/return. Please choose one of the followings,

☐ a. Sample Disposal: Crystal Pharma will dispose the samples by following RCRA and Solid/HAZ waste guidelines,

☐ b. Sample Storage: Crystal Pharmatech will keep samples until client's further notice, or disposal after 12 months if no further notice received from client.

☐ c. Sample Return: Crystal Pharma will return the samples to the client based on the information provided below.
Crystal Pharmatech is responsible for covering standard or normal shipping costs; however, Crystal Pharmatech is not responsible for expenses related to premium or expensive shipping methods.

Shipping Contact:
Contact Email:
Shipping Address:
Carrier's Account:
(FedEx, UPS, etc.)

6. Communication and Reporting

Crystal Pharmatech will provide regular Project updates and will hold meetings as desired by the Client. At project completion, Crystal Pharmatech will provide a final report including all characterization data and a clear discussion of results. The report will be sent within 4 weeks of the experiment completion date.

7. Pricing

Pricing is outlined in Table 1. Fifty percent (50%) of the service fee is invoiced after the proposal is approved. The remaining service fee will be invoiced upon delivery of the report. Any optional work will result in additional charges as per Table 2, which will be combined with the final invoice.

Crystal Pharmatech has estimated the time and resources necessary for the outlined activities, with pricing based on these assumptions. The quoted price includes materials, supplies, and waste, unless otherwise stated. Any additional or out-of-scope work due to unforeseen circumstances or client requests will require a client-approved Change Order before commencement. Any HPLC columns (if not included), unstocked chemicals, instrument accessories, or shipping expenses not listed will be billed at cost plus a 20% administrative fee.

All invoices are due in Net 30 days.

8. Site of Project Execution

The work outlined in this Proposal will be completed at our China facility. Please ensure your P.O. reflects our facility information below:

Crystal Pharmatech Co., Ltd
288 Jiangyun Road, Suzhou Industrial Park,



Crystal Pharmatech

Suzhou, China, 215123

9. Project Confirmation

The client needs to provide feedback within 10 business days of receiving our research report. Crystal Pharmatech will complete the report revision within one week after we receive the revision request. If the client doesn't provide feedback within the timeline, the project is considered closed, and the client agrees to pay the invoices.

10. Additional Contact Information

PO Managing: Wenting Ma
E-mail Address: pm@crystalpharmatech.com

Account Receivable: Yan Yu
E-mail Address: crystal_finance@crystalpharmatech.com

Crystal Pharmatech

Bill To: Nereid Therapeutics, Inc.
451 D Street, Suite 912
Boston, MA 02210
AP Phone: 617-315-0100
AP Email: AP@nereidtx.com

nereid

Purchase Order

THIS NUMBER MUST APPEAR ON ALL INVOICES, BILLS OF LADING AND PACKAGES
PO # 4011

Date: 3/27/2025

Vendor: Crystal Pharmatech Co Ltd
288 Jiangyun Road
SIP
Suzhou, China 215123
Account Number: N/A

Ship To: Nereid Therapeutics, Inc.
451 D Street, Suite 912
Boston, MA 02210
Attn: Vince Huber

Ship Via	FOB	Prepaid Freight	Delivery Date	Terms
Best Way	Destination	Prepay & Add		Net 10

Buyer	Requisitioner
Emily Keeler, ekeeler@bioprocure.com,	Vince Huber, vhuber@nereidtx.com, 9999999999

Line	Qty	U/M	Item Code/Description	Unit Price	Amount	Tax
1	1.00	EA	Desc: Co-crystal screening of NER-0119065. Total cost, including options is $31,000, as per Proposal ID CP540U09. Need On or Before: 4/3/2025 Note to Supplier: Proposal ID CP540U09 attached	31,000.00	31,000.00	No

Total	USD 31,000.00

John J. Wilk

Authorized Signature

Crystal Pharmatech Co,.Ltd
8/9F, 288 Jiangyun Road, Suzhou Industrial Park
Suzhou, China, 215123
Web: www.crystalpharmatech.com

Crystal Pharmatech

Business Confidential

Further evaluation of co-crystals hits

Quote Number: CP540U09 CO
Original PO Number: CP540U09 CO

Company:	Nereid Therapeutics Inc.	*Date:*	May 21, 2025
Client:	Ivan Efremov	*Issued by:*	Robert Wenslow
Email:	iefremov@nereidtx.com	*Email:*	Robert_wenslow@crystalphar matech-global.com
			Quotation valid for 60 days

Accepted and Approved for Crystal Pharmatech Co.,Ltd by:

Name (Print): Robert Wenslow Signature:
Title: VP of US BD Date: May 21, 2025

Accepted and Approved for Nereid Therapeutics Inc. by:
Name (Print): John F. Reilly Signature:
Title: Chief Scientific Officer Date: 22May2025

Changes are made to activities in the original work order of CP540U09 CO. The following activities will be added and are summarized in the following table:

Two-stage dissolution for 3 co-crystal hits:

- Evaluate two-stage dissolution in SGF-FaSSIF at 3 timepoints (2 hours in SGF; 0.5 and 4 hours after diluting to FaSSIF) for 3 salt/cocrystal hits. All the samples will be tested for concentration (HPLC), pH, and form conversion (XRPD).

Table 1: Cost, Timing, and Desired Material

Activity	Cost	Timeline (Weeks)	Material (g)
Change Order Total	$21,400	1	0.2
Original PO Amount	***$31,000***	1	
Total	***$52,400***	***1***	***0***

Crystal Pharmatech will use materials sent by Client before for this study and will provide updates and hold meetings as desired by client.

Crystal Pharmatech Co,.Ltd
8/9F, 288 Jiangyun Road, Suzhou Industrial Park
Suzhou, China, 215123
Web: www.crystalpharmatech.com



Crystal Pharmatech

Business Confidential

At project completion, Crystal Pharmatech will provide a final report including all results from previous study (CP540U09 CO). The report will be sent within 4 weeks from experiment completion date.

The original PO amount is $31,000 and the new total cost is adjusted to $52,400. The remaining service fee should be paid in full 1 month after the final report is confirmed.

Optional: Crystal Pharmatech FTE Team Model

As an alternative to change orders, Crystal Pharmatech offers the **FTE Team** service model. The **FTE Team** offers the highest level of speed and flexibility to adapt to changing project needs. Gain immediate access to any core service and the relevant expert with a single blanket PO billed monthly or quarterly. Pay only for work completed with no expiration on any unused FTE balance.

Please contact your business development representative if you are interested in the FTE Team model.

Crystal Pharmatech

Crystal Pharmatech Co Ltd

Address: 288 Jiangyun Road, SIP, Suzhou, China, 215123
Phone: 1-609-529-4135/ 609-604-8303
Website: www.crystalpharmatech.com
Email: pm@crystalpharmatech.com

INVOICE

DATE	03/31/2025
INVOICE #	CP540U09CCA
DUE DATE	04/30/2025

BILL TO:

Nereid Therapeutics, Inc.
451 D Street, Suite 912
Boston, MA, 02210
United States

QUANTITY	DESCRIPTION	UNIT PRICE	LINE TOTAL
0.5	Co-Crystal Screening	$23,000	$11,500
		TOTAL	**$11,500**

COMMENTS:

1. Total payment due in 30 days
2. Please include the invoice number on your wires
3. Down Payment for CP540U09_Co-Crystal Screening
4. PO #4011
5. Currency: USD
6. Please kindly ensure the payment should be made by the same legal entity in the signed proposal & this invoice

WIRE/ACH TRANSFER INSTRUCTIONS:

S.W.I.F.T Code: BKCHCNBJ95B
Bank Account Number: 527458302268
Bank Name: Bank of China, Suzhou industrial park sub-branch
Bank Address: 8 Suzhou Road, Suzhou Industrial Park, Suzhou, China
Company Name: Crystal Pharmatech Co Ltd

Thank You For Your Business!

Crystal Pharmatech

Crystal Pharmatech Co Ltd

Address: 288 Jiangyun Road, SIP, Suzhou, China, 215123
Phone: 1-609-529-4135/ 609-604-8303
Website: www.crystalpharmatech.com
Email: pm@crystalpharmatech.com

INVOICE

DATE	07/03/2025
INVOICE #	CP540U09CCB
DUE DATE	08/02/2025

BILL TO:

Nereid Therapeutics, Inc.
451 D Street, Suite 912
Boston, MA, 02210
United States

QUANTITY	DESCRIPTION	UNIT PRICE	LINE TOTAL
0.8	Co-Crystal Screening	$52,400	$40,900
		TOTAL	**$40,900**

COMMENTS:

1. Total payment due in 30 days
2. Please include the invoice number on your wires
3. Final Payment for CP540U09_Co-Crystal Screening
4. PO #4011
5. Currency: USD
6. Please kindly ensure the payment should be made by the same legal entity in the signed proposal & this invoice

WIRE/ACH TRANSFER INSTRUCTIONS:

S.W.I.F.T Code: BKCHCNBJ95B
Bank Account Number: 527458302268
Bank Name: Bank of China, Suzhou industrial park sub-branch
Bank Address: 8 Suzhou Road, Suzhou Industrial Park, Suzhou, China
Company Name: Crystal Pharmatech Co Ltd

Thank You For Your Business!

From: Wenfeng Xue
Sent: 2025年6月30日星期一 16:24
To: Vincent Huber
Cc: Ivan Efremov; Robert Wenslow; Lianfeng Huang; Shuai Wang
Subject: Report_CP540U09_NER-0119065 Cocrystal Screening_30Jun2025

Hi Vince,

The report of CP540U09_NER-0119065 Cocrystal Screening has been uploaded to the sharepoint folder (Nereid Therapeutics). If you have any comments on the report, please feel free to let us know.

Best regards,

Wenfeng

From: Ivan Efremov <iefremov@nereidtx.com>
Sent: Saturday, June 21, 2025 2:45 AM
To: Wenfeng Xue <wenfeng_xue@crystalpharmatech.com>; Vincent Huber <vhuber@nereidtx.com>
Cc: Robert Wenslow <Robert_wenslow@crystalpharmatech-global.com>; Lianfeng Huang <lianfeng_huang@crystalpharmatech.com>; Shuai Wang <shuai_wang@crystalpharmatech.com>
Subject: RE: Update 7_CP540U09_NER-0119065 Cocrystal Screening_11Jun2025

CAUTION: This email originated from **outside** of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Hi Wenfeng,
Please provide the report to wrap up this workstream. Thank you for your engagement and hard work.
Ivan.

From: Wenfeng Xue <wenfeng_xue@crystalpharmatech.com>
Sent: Thursday, June 19, 2025 9:04 AM
To: Vincent Huber <vhuber@nereidtx.com>
Cc: Ivan Efremov <iefremov@nereidtx.com>; Robert Wenslow <Robert_wenslow@crystalpharmatech-global.com>; Lianfeng Huang <lianfeng_huang@crystalpharmatech.com>; Shuai Wang <shuai_wang@crystalpharmatech.com>
Subject: RE: Update 7_CP540U09_NER-0119065 Cocrystal Screening_11Jun2025

Hi Vince,

Hope everything goes well! Just wondering whether you have any comments on the solubility data. The salt leads showed improved solubility than freebase in FaSSIF but the solubility was still relatively low (the highest solubility was 0.9 μg/mL (Esylate Type B)). If a TC is required to discuss the data and future plan, please feel free to let us know.

Now we are summarizing the data and planning to provide a report by 30Jun. If any other study is also needed, please feel free to let us know.

Best regards,

Wenfeng

From: Wenting Li
Sent: 2025年3月31日星期一 16:21
To: Vincent Huber; ap@nereidtx.com
Cc: PM; Robert Wenslow; Mandy Zhu; Crystal Finance
Subject: Invoice of down payment for CP540U09_PO#4011
Attachments: Invoice_CP540U09CCA_PO#4011_31Mar2025.pdf

Dear Vincent,

Enclosed please find the down payment invoice for CP540U09 ($11,500, 50% of proposal amount). Thanks and please feel free to let me know if you have any questions/suggestions on the invoice.

Best regards,
Wenting

Wenting Li, PMP **PMBO Department**
Crystal Pharmatech
www.crystalpharmatech.com

Crystal Pharmatech

This message contains information which may be confidential and privileged. Unless you are the addressee (or authorized to receive for the addressee), you may not use, copy or disclose to anyone the message or any information contained in the message. If you have received the message in error, please notify the sender immediately by replying to this message or calling +86 (512) 69561921, and delete the original message and any attachments from your electronic files. Thank you for your cooperation.

From: Wenting Li
Sent: Friday, March 28, 2025 11:24 AM
To: ekeeler@bioprocure.com
Cc: PM <pm@crystalpharmatech.com>; Robert Wenslow <Robert_wenslow@crystalpharmatech-global.com>; Mandy Zhu <menghuan_zhu@crystalpharmatech.com>
Subject: RE: Nereid Therapeutics, Inc. Purchase Order 4011

Hi Emily,

Thank you for providing the PO and proposal documents. We will refer to PO#4011 in future invoices for project CP540U09. Thanks and please feel free to let me know if you have any questions.

Best regards,
Wenting

Wenting Li, PMP **PMBO Department**
Crystal Pharmatech
www.crystalpharmatech.com

Crystal Pharmatech

This message contains information which may be confidential and privileged. Unless you are the addressee (or authorized to receive for the addressee), you may not use, copy or disclose to anyone the message or any information contained in the message. If you have received the message in error, please notify the sender immediately by replying to this message or calling +86 (512) 69561921, and delete the original message and any attachments from your electronic files. Thank you for your cooperation.

From: Wenting Li
Sent: 2025年7月3日星期四 17:54
To: Ivan Efremov; ap@nereidtx.com
Cc: Robert Wenslow; PM; Crystal Finance; Mandy Zhu
Subject: Invoice of final payment for CP540U09_PO#4011
Attachments: Invoice_CP540U09CCB_PO#4011_03Jul2025.pdf

Dear Ivan and AP Team,

Regarding project CP540U09, we're pleased to inform you that all studies have been completed. Please find attached the **final payment invoice**, covering the **remaining 50% of the proposal amount** along with the **change order amount**.

For internal control purposes, we were required to provide e-mail confirmation that you accept the invoice. If you accept the invoice, please kindly respond to this e-mail with **"I approve the invoice"** and arrange the payment at your earliest convenience.

If you have any concerns with the invoice, please feel free to contact us and we will address your concerns immediately.

Best regards,
Wenting

Wenting Li, PMP **PMBO Department**
Crystal Pharmatech
www.crystalpharmatech.com

Crystal Pharmatech

This message contains information which may be confidential and privileged. Unless you are the addressee (or authorized to receive for the addressee), you may not use, copy or disclose to anyone the message or any information contained in the message. If you have received the message in error, please notify the sender immediately by replying to this message or calling +86 (512) 69561921, and delete the original message and any attachments from your electronic files. Thank you for your cooperation.

From: Wenfeng Xue <wenfeng_xue@crystalpharmatech.com>
Sent: Monday, June 30, 2025 4:24 PM
To: Vincent Huber <vhuber@nereidtx.com>
Cc: Ivan Efremov <iefremov@nereidtx.com>; Robert Wenslow <Robert_wenslow@crystalpharmatech-global.com>; Lianfeng Huang <lianfeng_huang@crystalpharmatech.com>; Shuai Wang <shuai_wang@crystalpharmatech.com>
Subject: Report_CP540U09_NER-0119065 Cocrystal Screening_30Jun2025

Hi Vince,

The report of CP540U09_NER-0119065 Cocrystal Screening has been uploaded to the sharepoint folder (Nereid Therapeutics). If you have any comments on the report, please feel free to let us know.

Best regards,

Wenfeng

From: Ivan Efremov <iefremov@nereidtx.com>
Sent: 2025年7月4日星期五 22:41
To: Wenting Li
Cc: Robert Wenslow; PM; Crystal Finance; Mandy Zhu; Accounts Payable
Subject: RE: Invoice of final payment for CP540U09_PO#4011

CAUTION: This email originated from **outside** of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Hi Wenting,
Thank you for the granularity – we are on the same page. Our accounting team is copied on this email.
Ivan.

From: Wenting Li <wenting_li@crystalpharmatech.com>
Sent: Thursday, July 3, 2025 9:16 PM
To: Ivan Efremov <iefremov@nereidtx.com>
Cc: Robert Wenslow <Robert_wenslow@crystalpharmatech-global.com>; PM <pm@crystalpharmatech.com>; Crystal Finance <crystal_finance@crystalpharmatech.com>; Mandy Zhu <menghuan_zhu@crystalpharmatech.com>; Accounts Payable <ap@nereidtx.com>
Subject: RE: Invoice of final payment for CP540U09_PO#4011

Dear Ivan,

Thank you for your message.

Regarding CP540U09, in addition to the original scope of work, additional salt/cocrystal scale-up and evaluation have been conducted. A change order for this additional work was approved in May — please find the approved change order attached for your reference.

The invoice amount reflects both the remaining of the original PO and the approved change order amount ($11,500+$8,000+$21,400). For your reference, we have also attached a **work summary** outlining the completed activities under this project.

Please let us know if you have any further questions or need additional clarification.

Best regards,
Wenting

Wenting Li, PMP **PMBO Department**
Crystal Pharmatech
www.crystalpharmatech.com

Crystal Pharmatech

This message contains information which may be confidential and privileged. Unless you are the addressee (or authorized to receive for the addressee), you may not use, copy or disclose to anyone the message or any information contained in the message. If you have received the message in error, please notify the sender immediately by replying to this message or calling +86 (512) 69561921, and delete the original message and any attachments from your electronic files. Thank you for your cooperation.

From: Ivan Efremov <iefremov@nereidtx.com>
Sent: Thursday, July 3, 2025 9:30 PM